Sumitomo Dainippon Pharma Oncology, Inc. announced that the first patient has been dosed in the Phase I dose expansion portion of the study evaluating the investigational agent TP-1287, an oral cyclin-dependent kinase 9 inhibitor, in patients with sarcoma.
[Sumitomo Dainippon Pharma Oncology, Inc.]
7992332
{7992332:nan}
apa
50
1
168583
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
